271 related articles for article (PubMed ID: 30337229)
1. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Le-Nhat-Thuy G; Dinh TV; Pham-The H; Nguyen Quang H; Nguyen Thi N; Dang Thi TA; Hoang Thi P; Le Thi TA; Nguyen HT; Nguyen Thanh P; Le Duc T; Nguyen TV
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3741-3747. PubMed ID: 30337229
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
6. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
7. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
8. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
9. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
11. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
Li RD; Zhang X; Li QY; Ge ZM; Li RT
Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
Ding C; Chen S; Zhang C; Hu G; Zhang W; Li L; Chen YZ; Tan C; Jiang Y
Bioorg Med Chem; 2017 Jan; 25(1):27-37. PubMed ID: 27769671
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
15. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
El-Sherief HAM; Youssif BGM; Abbas Bukhari SN; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Eur J Med Chem; 2018 Aug; 156():774-789. PubMed ID: 30055463
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1
Cheng W; Wang S; Yang Z; Tian X; Hu Y
Drug Des Devel Ther; 2019; 13():3079-3089. PubMed ID: 31695326
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
Chandregowda V; Kush AK; Chandrasekara Reddy G
Eur J Med Chem; 2009 Jul; 44(7):3046-55. PubMed ID: 18771819
[TBL] [Abstract][Full Text] [Related]
20. Novel quinazolin-4(3H)-one linked to 1,2,3-triazoles: Synthesis and anticancer activity.
Safavi M; Ashtari A; Khalili F; Mirfazli SS; Saeedi M; Ardestani SK; Rashidi Ranjbar P; Barazandeh Tehrani M; Larijani B; Mahdavi M
Chem Biol Drug Des; 2018 Jul; 92(1):1373-1381. PubMed ID: 29637699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]